Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific St., Seattle, WA 98195, USA.
Gynecol Oncol. 2013 Sep;130(3):667-73. doi: 10.1016/j.ygyno.2013.06.023. Epub 2013 Jun 22.
While therapeutic vaccines for ovarian cancer represent only a small fraction of active clinical trials, growing interest in this area and the accumulated data supporting the use of vaccines in cancer treatment portend further expansion of trials incorporating these strategies. This review explores the rationale for the use of vaccines for the treatment of ovarian cancer. It examines vaccine platforms that have been investigated and reviews the data from these studies. We also highlight recently reported phase 2 and 3 clinical trials with clinical outcomes as endpoints. Finally, we consider directions for the next generation of vaccines in light of these findings and our emerging understanding of agents that may augment vaccine responses by targeting the immunosuppressive impact of the tumor microenvironment.
虽然卵巢癌的治疗性疫苗仅占活跃临床试验的一小部分,但该领域日益增长的兴趣以及支持疫苗在癌症治疗中应用的累积数据预示着将进一步扩大纳入这些策略的试验。本综述探讨了使用疫苗治疗卵巢癌的基本原理。它检查了已被研究的疫苗平台,并回顾了这些研究的数据。我们还突出了最近报道的 2 期和 3 期临床试验,其终点是临床结果。最后,鉴于这些发现以及我们对可能通过靶向肿瘤微环境的免疫抑制影响来增强疫苗反应的药物的新认识,我们考虑了下一代疫苗的发展方向。